.png){kind=small}
Nov 21, 2024
Cognitact Limited recently participated in the Gerontech and Innovation Expo cum Summit 2024 (GIES 2024), held from November 21 to 24 at the Hong Kong Convention and Exhibition Centre. Cognitact showcased its cutting-edge technology, PlasmarkAD®, a groundbreaking blood-based biomarkers test for Alzheimer’s disease.
GIES 2024 provided an invaluable opportunity for Cognitact to engage with the public and demonstrate the potential of PlasmarkAD® in revolutionizing the early detection of Alzheimer’s disease. Visitors had the chance learn about the innovative blood test, which simultaneously measures multi-protein biomarkers associated with Alzheimer’s pathology and utilized a proprietary machine learning algorithm to detect Alzheimer’s disease before symptom manifest.
At Cognitact, we are dedicated to community awareness and public education. During the four-day event, we had the privilege of connecting with many individuals. One elder expressed pride in Hong Kong's local university developing a groundbreaking blood test for Alzheimer’s disease, offering simpler and more accurate early detection for those with a family history, which could lead to timely treatment.
The GIES 2024 brought together industry leaders, healthcare professionals, researchers, and the general public to explore the latest advancements in gerontechnology and innovative solutions for enhancing the quality of life for aging populations.
Cognitact's participation in the event reaffirms its commitment to revolutionizing the field of Alzheimer's disease detection and leveraging world-leading technology to benefit the elderly society.
For more information about PlasmarkAD® and Cognitact Limited's other initiatives, please visit www.cogntiact.com or call (+852) 2116 1678.